Dr. Melanie Linn, DACVR-RO (previously Melanie Moore) at the MSU College of Veterinary Medicine is recruiting patients for a clinical trial that evaluates stereotactic radiation therapy to treat nonsurgical canine hepatocellular carcinomas. The trial offers a substantial financial benefit to clients--it covers most of the cost for radiation and the follow-up visits.
Supportive care for nonresectable HCCs in dogs has shown a median survival time of 9 months. Case reports and anecdotal evidence for stereotactic radiation to canine HCC suggests long-term control over 18 months with minimal adverse effects.
The goal of this study is to support the preliminary evidence and provide a protocol that can be used without advanced motion monitoring, which is technology that is not widely available in veterinary medicine.
- Dogs with a histologic- or cytologic-confirmed hepatocellular carcinoma
- Cytologic diagnosis is permitted if it provides a definitive diagnosis
- No diffuse HCC due to lack of discrete target
- No previous radiation therapy of this tumor
- Complete blood count (performed within past six weeks)
- Blood chemistry panel (performed within past six weeks)
- Thoracic radiographs (or other thoracic imaging, performed within past six weeks)
Dogs will undergo a specialized planning CT scan of the liver, three stereotactic radiation treatments, and routine rechecks for the first year after radiation. At six months, MSU also will perform a recheck CT scan. All scans and radiation treatments will be done under general anesthesia. Most of these costs will be covered by the trial.
- The trial is enrolling patients now through June 30, 2024.
- We will notify you if the trial fully enrolls.